Visceral fat is referred to as the fat stored on the abdominal cavity of the body, and it is also the most dangerous kind of fat we can have. But the good news is that it can be reduced or prevented with diet and exercise, and a new report reveals what to drink that can help.
Express reports that a certain drink can be good for helping reduce the visceral fat in the body. A study was conducted in Japan, on the link between vinegar and weight loss. The participants were asked to drink a beverage containing varying doses of vinegar - 750mg and 1500 mg or 0mg placebo - apple cider vinegar in particular, because it tasted better. The participants drank these drinks over a period of 12 weeks.
At the end of the 12 weeks, the researchers found that the participants who drank both kinds of apple cider vinegar doses experienced weight loss and reduced body fat percentage compared to those who only drank placebo.
Vinegar has always been used as a remedy for many health issues, and reducing visceral fat is one of them. Taking some vinegar or apple cider vinegar a day can not only reduce visceral fat, but it can lower the risks of conditions like hypertension, high blood pressure, even lowering triglyceride levels or bad cholesterol in the body.
Aside from apple cider vinegar, green tea has also been proven to help reduce visceral fat in the body. It is one of the healthiest drinks in the world and has always been known to help in weight loss, therefore, reducing visceral fat. This is because green tea is full of antioxidants as well as caffeine, a compound known to help burn fat.
There are many studies that back up this fact. One study about the catechins found in green tea revealed that while overall weight loss is substantial, most of it was visceral fat. While it may not seem much for those looking to drastically lose weight, green tea or apple cider vinegar still helps in weight loss, and best paired with a balanced diet and exercise.


Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 



